CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Ispinesibdrug
Likely dose
Ispinesib 18 mg/m² intravenouslyAI-extracted
Key inclusion· 2
  • ✓Stage IIIB or Stage IV breast cancer
  • ✓Prior treatment with both anthracycline and taxane therapy
Key exclusion· 1
  • ✕Currently receiving other anti-cancer therapy agents

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00089973
NCT00089973Phase 2Completed
CompareCT.gov

Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer

GlaxoSmithKline·interventional·Posted Aug 20, 2004·Updated Feb 26, 2018

In Brief

A Phase 2 clinical trial evaluating Ispinesib for Neoplasms, Breast. Completed, enrolled 50 participants across 13 sites in 5 countries.

Detailed Summary

The purpose of this research study is to find how breast cancer responds to the investigational drug, Ispinesib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. In particular, this study will try is to find the answers to the following research questions: 1. Does breast cancer respond to Ispinesib? 2. What are the side effects of Ispinesib? 3. How much Ispinesib is in the blood at specific times after it is taken?

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Breast
CountriesBelgium, Malaysia, Singapore, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 20, 2004
Enrollment StartJun 30, 2004
Primary CompletionAug 25, 2006
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 21.9 years ago

Interventions

Ispinesibdrug

Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).